艾尔巴韦/格拉瑞韦治疗1b型儿童慢性丙型肝炎5例疗效分析

肝脏 ›› 2023, Vol. 28 ›› Issue (9): 1041-1043.

艾尔巴韦/格拉瑞韦治疗1b型儿童慢性丙型肝炎5例疗效分析

刘立, 李梅, 常丽仙, 刘春云, 李惠敏, 方铭, 李俊义

650041 昆明市第三人民医院云南省传染性疾病临床医学中心(刘立,常丽仙,刘春云,李惠敏,李俊义);655500 云南省富源县人民医院感染科(李梅,方铭)

收稿日期:2022-11-14 出版日期:2023-09-30 发布日期:2023-10-24
通讯作者: 刘春云,Email:751440760@qq.com
作者简介:共同第一作者:李梅

Clinical analysis of 5 children cases of chronic hepatitis C genotype 1b treated with elbasvir/grazoprevir

LIU Li, LI Mei, CHANG Li-xian, LIU Chun-yun, LI Hui-min, FANG Ming, LI Jun-yi

Yunnan Infectious Diseases Clinical Medical Center, the Third People's Hospital of Kunming, Kunming 650041,China; Department of Infectious Diseases, Fuyuan County People's Hospital, Yunnan 655500, China

Received:2022-11-14 Online:2023-09-30 Published:2023-10-24
Contact: LIU Chun-yun, Email:751440760@qq.com

摘要/Abstract

摘要： 目的探讨艾尔巴韦/格拉瑞韦(elbasvir/grazoprevir, EBR/GZR)治疗1b型儿童慢性丙型肝炎(chronic hepatitis C, CHC)的疗效和短期安全性。方法收集2019年1月—2022年3月的基因1b型儿童CHC,给予EBR/GZR治疗12周,停药随访12周的生化学指标、病毒学指标等。主要疗效指标为治疗结束后随访12周时患儿获得持续病学应答(sustained virological response, SVR)和治疗期间的不良反应发生的情况。结果 5例儿童CHC,男3例,女2年,平均年龄7.68岁。母亲传播2例、祖父传播1例、父亲传播1例、1例不详。EBR/GZR治疗4周、8周、12周和停药12周的SVR分别为60%、100%、100%、100%。丙氨酸氨基转移酶和天冬氨酸氨基转移酶在治疗4周时均恢复正常。不良反应中,1例出现轻微恶心。结论 EBR/GZR治疗儿童1b型CHC的疗效和短期安全性较好。

关键词: 慢性丙型肝炎, 儿童, 艾尔巴韦/格拉瑞韦, 疗效, 安全性

Abstract: Objective To explore the efficacy and short-term safety of elbasvir/grazoprevir (EBR/GZR) in the treatment of chronic hepatitis C (CHC) genotype 1b in children.Methods The children infected with genotype 1b hepatitis C virus enrolled from January 2019 to March 2022 were given EBR/GZR treatment for 12 weeks, and followed-up for biochemical and virological indicators for 12 weeks after drug withdrawal. The main efficacy indicators were the sustained virological response (SVR) obtained at the end of the treatment and the occurrence of adverse reactions during the treatment. Results There were 5 CHC children, with 3 males and 2 females, and an average of 7.68 years. There were 2 cases of mother transmission, 1 of grandfather transmission, 1 of father transmission, and 1 was unknown of the transmission route. The SVR of EBR/GZR treatment for 4, 8, 12 weeks, and 12 weeks after drug withdrawal were 60%, 100%, 100% and 100%, respectively. In all patients alanine transferase and aspartate transferase returned to normal after 4 weeks of treatment. For the adverse reactions, there was only 1 case with slightly nausea. Conclusion EBR/GZR was effective and safe for the treatment of CHC genotype 1b children.

Key words: Chronic hepatitis C, Children, Elbasvir/grazoprevir, Curative effect, Safety

刘立, 李梅, 常丽仙, 刘春云, 李惠敏, 方铭, 李俊义. 艾尔巴韦/格拉瑞韦治疗1b型儿童慢性丙型肝炎5例疗效分析[J]. 肝脏, 2023, 28(9): 1041-1043.

LIU Li, LI Mei, CHANG Li-xian, LIU Chun-yun, LI Hui-min, FANG Ming, LI Jun-yi. Clinical analysis of 5 children cases of chronic hepatitis C genotype 1b treated with elbasvir/grazoprevir[J]. Chinese Hepatolgy, 2023, 28(9): 1041-1043.

参考文献

[1] Schmelzer J, Dugan E, Blach S, et al. Global prevalence of hepatitis C virus in children in 2018: a modelling study. Lancet Gastroenterol Hepatol.2020,5(4):374-392.
[2] Indolfi G, Easterbrool P, Dusheiko G, et al. Hepatitis C virus infection in children and adolescents. Lancet Gastroenterol Hepatol,2019,4:477-487.
[3] Dong Y, Wang L, Burgner DP, et al. Infectous diseases in children and adolescents in China: analysis of national surveillance data from 2008 to 2017. BMJ,2020,369:m1043.
[4] Lagging M, Wejstal R, Norkrans G, et al. Treatment of hepatitis C virus infection for adults and children: updated Swedish consensus recommendations. Infect Dis (Lond).2016,48(4):251-261.
[5] 李元元, 史继静, 王福生, 等. 直接抗病毒药物对慢性丙型肝炎特殊人群的治疗进展. 传染病信息,2017,30(2):70-74.
[6] Squires JE, Balistreri WF. Hepatitis C virus infection in children and adolescents. HepatolCommun,2017,1(2):87-98.
[7] 温中翔, 朱鹏, 王宇明. 儿童丙型肝炎病毒感染临床研究. 临床肝胆病杂志,2012,28(12):888-892.
[8] AASLD-IDSA. Recommendations for Testing, anaging, and Treating Hepatitis C.https://www.hcvguidelines.org/unique-populations/children. Accessed May 2022.[9] Pawlotsky JM, Negro F, Aghemo A, et al. EASL recommendations on treatment of hepatitis C: final update of the series. Journal of hepatology,2020,73(5):1170-1218.
[10] Rosenthal P, Schwarz KB, Gonzalez-Peralta RP, et al. Sofosbuvir+ribavirin for 12 or 24 weeks is safe and effective in children 3 to <12 years old with genotype 2 or genotype 3 chronic hepatitis C infection.Hepatology,2018,68(S1):1048A-1049A.
[11] Younossi ZM, Stepanova M, Schwarz KB, et al. Quality of life in adolescents with hepatitis C treated with fofosbuvir and ribavirin. J Viral Hepat,2018,25(4):354-362.
[12] 宁会彬, 刘俊平, 靳慧鸣, 等. 直接抗病毒药物治疗儿童丙型肝炎1例报告. 临床肝胆病杂志,2019,35(1):164-165.
[13] 陈娜, 周泉, 蔡乐斌. 直接抗病毒药物治愈儿童慢性丙型肝炎1例. 中华肝脏病杂志,2021,29(12):1196-1197.
[14] 王丽旻, 黄美颖, 董漪, 等. 索磷布韦为基础的直接抗病毒药物治疗儿童慢性丙型肝炎的疗效及安全性. 中华实验和临床病毒学杂志,2022,36(02):195-198.
[15] ClinicalTrials.gov. Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants With Chronic Hepatitis C Infection (MK-5172-079). [EB/OL]. https://clinicaltrials.gov/ct2/show/NCT03379506?term=NCT03379506&draw=2&rank=1